The study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab (PemPBev) and paclitaxel/carboplatin/bevacizumab (PacCBev) as first‐line therapy for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC) patients… Click to show full abstract
The study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab (PemPBev) and paclitaxel/carboplatin/bevacizumab (PacCBev) as first‐line therapy for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC) patients with wild‐type driver genes in a real‐world setting.
Keywords:
bevacizumab;
pemetrexed carboplatin;
cisplatin bevacizumab;
carboplatin;
cancer;
carboplatin cisplatin
Journal Title: Thoracic Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thoracic Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!